Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5,849 INR | +1.18% | -0.23% | +1.05% |
05:00am | Indian shares set to rise at open; Fed minutes eyed | RE |
May. 21 | Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.05% | 11.56B | B+ | ||
+37.78% | 723B | C+ | ||
+31.61% | 598B | B | ||
-3.51% | 364B | C+ | ||
+19.94% | 331B | B- | ||
+5.14% | 288B | C+ | ||
+16.13% | 244B | B+ | ||
-4.50% | 208B | A+ | ||
+10.02% | 210B | B- | ||
+9.32% | 169B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DRREDDY Stock
- Ratings Dr. Reddy's Laboratories Limited